Prime

Type your tag names separated by a space and hit enter

TIAM1 variants improve clinical outcome in neuroblastoma.

Abstract

Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer. Neuroblastoma is a tumor of the peripheral sympathetic nervous system for which only a few driver alterations have been described including MYCN amplification and ALK mutations. We assessed 106 primary neuroblastoma tumors by next generation sequencing using a customized amplicon-based gene panel. Our results reveal that genetic variants in TIAM1 gene associate with better clinical outcome, suggesting a role for these TIAM1 variants in preventing progression of this disease. The detected variants are located within the different domains of TIAM1 that signal to the upstream regulator RAS and downstream effector molecules MYC and RAC, which are all implicated in neuroblastoma etiology and progression. Clinical outcome was improved in tumors where a TIAM1 variant was present concomitantly with either ALK mutation or MYCN amplification. Given the function of these signaling molecules in cell survival, proliferation, differentiation and neurite outgrowth, our data suggest that the TIAM1-mediated network is essential to neuroblastoma and thus, inhibiting TIAM1 reflects a rational strategy for improving therapy efficacy in neuroblastoma.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Laboratory of Cellular and Molecular Biology, Instituto de Investigación Sanitaria La Fe, Spain.

    ,

    Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Spain. Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Spain.

    ,

    Biostatistics Unit, Instituto de Investigación Sanitaria La Fe, Spain.

    ,

    Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Leioa, Spain. Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain. IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

    ,

    Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Spain. Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Spain.

    ,

    Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Spain. Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Spain.

    Laboratory of Cellular and Molecular Biology, Instituto de Investigación Sanitaria La Fe, Spain. Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Spain.

    Source

    Oncotarget : 2017 Apr 03 pg

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    28423360